Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell) in Infants
NCT02231632Phase 3Completed
- Sponsor
- Institute of Medical Biology
- Start
- Jan 2011
- Primary completion
- Mar 2012
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of Oral polio vaccine in poliomyelitis (2 arms), sponsored by Institute of Medical Biology. Primary endpoint: Comparison of virogene VP1 genovariation between vaccinal I-III Sabin strains and poliovirus separated from faeces up to 90 days. Started Jan 2011; status: completed.
02
Drugs
Oral polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT02231632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231632.